Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
Rebecca AraujoAcute Lymphoblastic Leukemia | September 23, 2024
The phase Ib/II FELIX trial found that obe-cel is effective for the treatment of relapsed or refractory adult B-cell ALL.
Read More
Elias Jabbour, MDAcute Lymphoblastic Leukemia | September 10, 2024
In the FELIX trial, obe-cel, a CAR-T therapy, achieved a 78% response rate and a 97% MRD negativity rate.
Melissa BadamoAcute Lymphoblastic Leukemia | September 5, 2024
Researchers identified several risk factors that predicted thrombosis in adults with ALL.
Melissa BadamoAcute Lymphoblastic Leukemia | September 5, 2024
A study described how the implementation of tisa-cel has affected treatment outcomes in B-ALL.
Melissa BadamoAcute Lymphoblastic Leukemia | September 5, 2024
MRD-negative CR status was able to predict long-term survival in newly diagnosed PH+ ALL.
Patrick DalyAcute Lymphoblastic Leukemia | September 16, 2024
Of the 127 patients who received obe-cel infusion, 74% achieved CR/CRi and 95% had MRD negativity.
Advertisement
Patrick DalyAcute Lymphoblastic Leukemia | July 2, 2024
The US FDA approved blinatumomab for the treatment of CD19-positive, Philadelphia chromosome-negative B-cell precursor ALL.
Andrew MorenoAcute Lymphoblastic Leukemia | June 6, 2024
Investigators identified pre- and postinfusion factors linked to severe hematotoxicity, as defined by EHA/EBMT criteria.
Elias Jabbour, MDPrint | May 22, 2024
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
Michel Zwaan, MD, PhDAcute Lymphoblastic Leukemia | April 22, 2024
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
Melissa BadamoAcute Myeloid Leukemia | April 9, 2024
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Blood Cancers Today Staff WritersAcute Lymphoblastic Leukemia | September 30, 2024
Efficacy was based on the MRD-negative CR rate at the end of induction.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse: MRD | July 26, 2024
Elias Jabbour, MD, joined "The HemOnc Pulse" to discuss the function of MRD in treating ALL.
Blood Cancers Today Staff WritersAcute Lymphoblastic Leukemia | March 6, 2024
The efficacy of inotuzumab ozogamicin was assessed in a multicenter, single-arm, open-label study in 53 pediatric patients.
Melissa BadamoAcute Myeloid Leukemia | May 21, 2024
UM171 promotes degradation of the CoREST1 complex and reduces levels of chromatin-bound MYC.
Patrick DalyAcute Lymphoblastic Leukemia | May 21, 2024
Most patients in the lower-dose group achieved complete remission or complete remission with partial hematologic recovery.
Melissa BadamoAcute Myeloid Leukemia | March 1, 2024
The percentage of KMT2A-altered cells decreased from 59.2% to 8.1% after treatment with JNJ-75276617.
Melissa BadamoAcute Lymphoblastic Leukemia | February 23, 2024
53.8% of patients treated with blinatumomab achieved MRD negativity within a median of 3.1 months, as detected with clonoSEQ.
Blood Cancer TalksAcute Myeloid Leukemia | March 4, 2024
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Leah SherwoodAcute Lymphoblastic Leukemia | January 31, 2024
The past two decades have witnessed a rapid change in the treatment of acute lymphoblastic leukemia.
Advertisement
Advertisement
Editorial Board